Alembic Pharmaceuticals has entered into a development and license agreement with Accu-Break Pharmaceuticals, Inc., (ABP) USA to develop new brand products that will use ABP's innovative Accu-Break tablet technologies.

ABP's patented Accu-Break tablets can be split easily by hand into exact smaller doses to provide maximum flexibility, and to make it easier and safer for patients and caregivers to adjust their dosage. The first product that ABP will seek US FDA marketing approval for is an Accu-Break-formatted version of the popular anticogulant medication warfarin.

ABP, based in Plantatin, Florida, is a technology licensing and product development company. It has invented, developed and patented a suite of novel Accu-Break technologies that enable pharmaceutical tablets to be made that can be subdivided by hand into accurate partial doses with the intent of making it easier and safer for patients to adjust their dose. ABP currently has 48 patents issued and 22 patents pending worldwide.